Back to top

Humacyte announces preclinical data on CTEV use

Humacyte (HUMA) announced the publication of new preclinical data as part of a study evaluating the coronary tissue engineered vessel, CTEV, as a c...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Humacyte, Inc. (HUMA)